201
|
NEUMANN HARTMUTP, BENDER BERNHARDU, BERGER DIETMARP, LAUBENBERGER JORG, SCHULTZE-SEEMANN WOLFGANG, WETTERAUER ULRICH, FERSTL FRANZJOSEF, HERBST EBERHARDW, SCHWARZKOPF GEORG, HES FREDERIKJ, LIPS J. M. CORNELIS, LAMIELL JAMESM, MASEK OTAKAR, RIEGLER PETER, MUELLER BARBARA, GLAVAC DAMJAN, BRAUCH HILTRUD. PREVALENCE, MORPHOLOGY AND BIOLOGY OF RENAL CELL CARCINOMA IN VON HIPPEL-LINDAU DISEASE COMPARED TO SPORADIC RENAL CELL CARCINOMA. J Urol 1998. [DOI: 10.1016/s0022-5347(01)62509-6] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- HARTMUT P.H. NEUMANN
- From the Departments of Medicine, Radiology, Urology and Pathology, Albert-Ludwigs-Universitat, Freiburg and Laboratory of Oncology, Department of Gynecology, University of Hamburg, Hamburg, Germany, Department of Medicine, University Hospital Utrecht, The Netherlands, United States Army Medical Department Center and School, Fort Sam Houston, Texas, Department of Radiology, Community Hospital, Zlin, Czech Republic, Department of Nephrology, Community Hospital, Bolzano, Italy, and Institute of
| | - BERNHARD U. BENDER
- From the Departments of Medicine, Radiology, Urology and Pathology, Albert-Ludwigs-Universitat, Freiburg and Laboratory of Oncology, Department of Gynecology, University of Hamburg, Hamburg, Germany, Department of Medicine, University Hospital Utrecht, The Netherlands, United States Army Medical Department Center and School, Fort Sam Houston, Texas, Department of Radiology, Community Hospital, Zlin, Czech Republic, Department of Nephrology, Community Hospital, Bolzano, Italy, and Institute of
| | - DIETMAR P. BERGER
- From the Departments of Medicine, Radiology, Urology and Pathology, Albert-Ludwigs-Universitat, Freiburg and Laboratory of Oncology, Department of Gynecology, University of Hamburg, Hamburg, Germany, Department of Medicine, University Hospital Utrecht, The Netherlands, United States Army Medical Department Center and School, Fort Sam Houston, Texas, Department of Radiology, Community Hospital, Zlin, Czech Republic, Department of Nephrology, Community Hospital, Bolzano, Italy, and Institute of
| | - JORG LAUBENBERGER
- From the Departments of Medicine, Radiology, Urology and Pathology, Albert-Ludwigs-Universitat, Freiburg and Laboratory of Oncology, Department of Gynecology, University of Hamburg, Hamburg, Germany, Department of Medicine, University Hospital Utrecht, The Netherlands, United States Army Medical Department Center and School, Fort Sam Houston, Texas, Department of Radiology, Community Hospital, Zlin, Czech Republic, Department of Nephrology, Community Hospital, Bolzano, Italy, and Institute of
| | - WOLFGANG SCHULTZE-SEEMANN
- From the Departments of Medicine, Radiology, Urology and Pathology, Albert-Ludwigs-Universitat, Freiburg and Laboratory of Oncology, Department of Gynecology, University of Hamburg, Hamburg, Germany, Department of Medicine, University Hospital Utrecht, The Netherlands, United States Army Medical Department Center and School, Fort Sam Houston, Texas, Department of Radiology, Community Hospital, Zlin, Czech Republic, Department of Nephrology, Community Hospital, Bolzano, Italy, and Institute of
| | - ULRICH WETTERAUER
- From the Departments of Medicine, Radiology, Urology and Pathology, Albert-Ludwigs-Universitat, Freiburg and Laboratory of Oncology, Department of Gynecology, University of Hamburg, Hamburg, Germany, Department of Medicine, University Hospital Utrecht, The Netherlands, United States Army Medical Department Center and School, Fort Sam Houston, Texas, Department of Radiology, Community Hospital, Zlin, Czech Republic, Department of Nephrology, Community Hospital, Bolzano, Italy, and Institute of
| | - FRANZ JOSEF FERSTL
- From the Departments of Medicine, Radiology, Urology and Pathology, Albert-Ludwigs-Universitat, Freiburg and Laboratory of Oncology, Department of Gynecology, University of Hamburg, Hamburg, Germany, Department of Medicine, University Hospital Utrecht, The Netherlands, United States Army Medical Department Center and School, Fort Sam Houston, Texas, Department of Radiology, Community Hospital, Zlin, Czech Republic, Department of Nephrology, Community Hospital, Bolzano, Italy, and Institute of
| | - EBERHARD W. HERBST
- From the Departments of Medicine, Radiology, Urology and Pathology, Albert-Ludwigs-Universitat, Freiburg and Laboratory of Oncology, Department of Gynecology, University of Hamburg, Hamburg, Germany, Department of Medicine, University Hospital Utrecht, The Netherlands, United States Army Medical Department Center and School, Fort Sam Houston, Texas, Department of Radiology, Community Hospital, Zlin, Czech Republic, Department of Nephrology, Community Hospital, Bolzano, Italy, and Institute of
| | - GEORG SCHWARZKOPF
- From the Departments of Medicine, Radiology, Urology and Pathology, Albert-Ludwigs-Universitat, Freiburg and Laboratory of Oncology, Department of Gynecology, University of Hamburg, Hamburg, Germany, Department of Medicine, University Hospital Utrecht, The Netherlands, United States Army Medical Department Center and School, Fort Sam Houston, Texas, Department of Radiology, Community Hospital, Zlin, Czech Republic, Department of Nephrology, Community Hospital, Bolzano, Italy, and Institute of
| | - FREDERIK J. HES
- From the Departments of Medicine, Radiology, Urology and Pathology, Albert-Ludwigs-Universitat, Freiburg and Laboratory of Oncology, Department of Gynecology, University of Hamburg, Hamburg, Germany, Department of Medicine, University Hospital Utrecht, The Netherlands, United States Army Medical Department Center and School, Fort Sam Houston, Texas, Department of Radiology, Community Hospital, Zlin, Czech Republic, Department of Nephrology, Community Hospital, Bolzano, Italy, and Institute of
| | - CORNELIS LIPS J. M.
- From the Departments of Medicine, Radiology, Urology and Pathology, Albert-Ludwigs-Universitat, Freiburg and Laboratory of Oncology, Department of Gynecology, University of Hamburg, Hamburg, Germany, Department of Medicine, University Hospital Utrecht, The Netherlands, United States Army Medical Department Center and School, Fort Sam Houston, Texas, Department of Radiology, Community Hospital, Zlin, Czech Republic, Department of Nephrology, Community Hospital, Bolzano, Italy, and Institute of
| | - JAMES M. LAMIELL
- From the Departments of Medicine, Radiology, Urology and Pathology, Albert-Ludwigs-Universitat, Freiburg and Laboratory of Oncology, Department of Gynecology, University of Hamburg, Hamburg, Germany, Department of Medicine, University Hospital Utrecht, The Netherlands, United States Army Medical Department Center and School, Fort Sam Houston, Texas, Department of Radiology, Community Hospital, Zlin, Czech Republic, Department of Nephrology, Community Hospital, Bolzano, Italy, and Institute of
| | - OTAKAR MASEK
- From the Departments of Medicine, Radiology, Urology and Pathology, Albert-Ludwigs-Universitat, Freiburg and Laboratory of Oncology, Department of Gynecology, University of Hamburg, Hamburg, Germany, Department of Medicine, University Hospital Utrecht, The Netherlands, United States Army Medical Department Center and School, Fort Sam Houston, Texas, Department of Radiology, Community Hospital, Zlin, Czech Republic, Department of Nephrology, Community Hospital, Bolzano, Italy, and Institute of
| | - PETER RIEGLER
- From the Departments of Medicine, Radiology, Urology and Pathology, Albert-Ludwigs-Universitat, Freiburg and Laboratory of Oncology, Department of Gynecology, University of Hamburg, Hamburg, Germany, Department of Medicine, University Hospital Utrecht, The Netherlands, United States Army Medical Department Center and School, Fort Sam Houston, Texas, Department of Radiology, Community Hospital, Zlin, Czech Republic, Department of Nephrology, Community Hospital, Bolzano, Italy, and Institute of
| | - BARBARA MUELLER
- From the Departments of Medicine, Radiology, Urology and Pathology, Albert-Ludwigs-Universitat, Freiburg and Laboratory of Oncology, Department of Gynecology, University of Hamburg, Hamburg, Germany, Department of Medicine, University Hospital Utrecht, The Netherlands, United States Army Medical Department Center and School, Fort Sam Houston, Texas, Department of Radiology, Community Hospital, Zlin, Czech Republic, Department of Nephrology, Community Hospital, Bolzano, Italy, and Institute of
| | - DAMJAN GLAVAC
- From the Departments of Medicine, Radiology, Urology and Pathology, Albert-Ludwigs-Universitat, Freiburg and Laboratory of Oncology, Department of Gynecology, University of Hamburg, Hamburg, Germany, Department of Medicine, University Hospital Utrecht, The Netherlands, United States Army Medical Department Center and School, Fort Sam Houston, Texas, Department of Radiology, Community Hospital, Zlin, Czech Republic, Department of Nephrology, Community Hospital, Bolzano, Italy, and Institute of
| | - HILTRUD BRAUCH
- From the Departments of Medicine, Radiology, Urology and Pathology, Albert-Ludwigs-Universitat, Freiburg and Laboratory of Oncology, Department of Gynecology, University of Hamburg, Hamburg, Germany, Department of Medicine, University Hospital Utrecht, The Netherlands, United States Army Medical Department Center and School, Fort Sam Houston, Texas, Department of Radiology, Community Hospital, Zlin, Czech Republic, Department of Nephrology, Community Hospital, Bolzano, Italy, and Institute of
| |
Collapse
|
202
|
PREVALENCE, MORPHOLOGY AND BIOLOGY OF RENAL CELL CARCINOMA IN VON HIPPEL-LINDAU DISEASE COMPARED TO SPORADIC RENAL CELL CARCINOMA. J Urol 1998. [DOI: 10.1097/00005392-199810000-00011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
203
|
Chang JH, Spraul CW, Lynn ML, Drack A, Grossniklaus HE. The two-stage mutation model in retinal hemangioblastoma. Ophthalmic Genet 1998; 19:123-30. [PMID: 9810567 DOI: 10.1076/opge.19.3.123.2185] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
BACKGROUND The two-stage mutation model involving successive inactivation of both alleles of a tumor suppressor gene was originally proposed by Knudson, who analyzed the age incidence curves for unilateral and bilateral retinoblastoma, and suggested that hereditary tumors arise by a single somatic event superimposed on a defective genetic background and sporadic tumors by a two-stage somatic process. In this study, the age-incidence curve of patients with retinal hemangioblastoma with and without associated von Hippel-Lindau disease were analyzed. METHODS We reviewed the literature between 1964 and 1998 to find all reported cases of retinal hemangioblastoma and classified patients in a type A group (n = 223) when associated with von Hippel-Lindau disease and a type B group (n = 30) when not associated with von Hippel-Lindau disease. We analyzed and compared the age incidence of these two groups. RESULTS There was a statistically significant difference between the mean age at diagnosis of retinal hemangioblastoma in the two groups, i.e., 48.4 +/- 16.6 years for type B patients and 24.9 +/- 12.0 years for type A patients (p < 0.0001). The age incidence curve for type A retinal hemangioblastoma fit a first-order equation (log S = 0.411-0.034t) with r = 0.97, indicating a single somatic mutation, whereas the age incidence curve for type B retinal hemangioblastoma fit a second-order equation (log S = 0.184-2.25 x 10(-4)t2) with r = 0.97, indicating two somatic mutations. CONCLUSIONS Type B (sporadic) retinal hemangioblastoma may arise from two separate somatic mutations inactivating both alleles at the von Hippel-Lindau locus, whereas patients with von Hippel-Lindau disease (type A) inherit a defective allele and require only one additional somatic mutation.
Collapse
Affiliation(s)
- J H Chang
- Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA, USA
| | | | | | | | | |
Collapse
|
204
|
Abstract
Studies of families with inherited carcinomas have provided powerful tools to identify the genes involved in the pathogenesis of human cancers. In this review, we summarize the clinical, pathological, and genetic characteristics of the inherited carcinomas of the kidney. We emphasize the observation that different genes predispose to histologically different types of renal carcinoma. Hereditary papillary renal carcinoma, a recently described inherited disorder, is discussed in detail along with the predisposing gene, the MET protooncogene. The data support a classification of renal carcinomas based on molecular genetics.
Collapse
Affiliation(s)
- B Zbar
- Laboratory of Immunobiology, NCI-Frederick Cancer Research and Development Center, Maryland 21702, USA
| | | |
Collapse
|
205
|
Abstract
A total of 146 intragenic germline mutations of the von Hippel-Lindau (VHL) gene are known and this figure is still increasing. To date, information for mutation-specific genetic counselling is insufficient, since either the total number of carriers is very low or clinical information and investigation of symptomatic and asymptomatic is incomplete. This review summarizes all known mutations and includes the centres which performed the mutation analyses and may provide further information regarding specific mutations.
Collapse
Affiliation(s)
- H P Neumann
- Department of Nephrology and Hypertension, University of Freiburg, Germany.
| | | |
Collapse
|
206
|
Affiliation(s)
- G E Tomlinson
- University of Texas Southwestern Medical Center, Department of Pediatrics, Dallas 75235-9063, USA
| |
Collapse
|
207
|
Li C, Weber G, Ekman P, Lagercrantz J, Norlen BJ, Akerström G, Nordenskjöld M, Bergerheim US. Germline mutations detected in the von Hippel-Lindau disease tumor suppressor gene by Southern blot and direct genomic DNA sequencing. Hum Mutat 1998; Suppl 1:S31-3. [PMID: 9452032 DOI: 10.1002/humu.1380110111] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- C Li
- Department of Urology, Karolinska Hospital, Stockholm, Sweden
| | | | | | | | | | | | | | | |
Collapse
|
208
|
Curley SA, Lott ST, Luca JW, Frazier ML, Killary AM. Surgical decision-making affected by clinical and genetic screening of a novel kindred with von Hippel-Lindau disease and pancreatic islet cell tumors. Ann Surg 1998; 227:229-35. [PMID: 9488521 PMCID: PMC1191240 DOI: 10.1097/00000658-199802000-00012] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVE We report a unique, previously undescribed multigeneration kindred with von Hippel-Lindau (VHL) disease in whom clinical or genetic screening led to the detection of surgically resectable neoplastic disease in several family members. SUMMARY BACKGROUND DATA Patients with VHL disease have a propensity to develop neoplasms of several different organ sites. Retinal angiomas, cerebellar and spinal hemangioblastomas, solid organ cysts, and renal carcinoma are common lesions; pheochromocytomas and pancreatic islet cell tumors occur less frequently but are important causes of morbidity and mortality. METHODS A detailed pedigree was constructed based on clinical screening and family history that describes the development of pancreatic islet cell tumors in four of five female siblings. VHL mutation analysis was performed in an attempt to determine if genotype-phenotype correlations could be made in this interesting family. RESULTS The age of onset of VHL-associated neoplasms for three affected siblings was in the third decade of life and in the fourth decade for the fourth sibling. The mother of the four siblings affected with pancreatic tumors developed bilateral pheochromocytomas in the seventh decade of life; she has no pancreatic or kidney tumors. We identified maternal transmission of a missense mutation in codon 238 in exon 3 of the VHL gene in the four affected siblings with pancreatic islet cell tumors. Mutation screening on unaffected family members showed no abnormalities in the VHL gene. Interestingly, one of the four affected siblings had no evidence of VHL on her initial clinical screening evaluation; however, she was followed closely because of her mutated VHL gene. Four years after initial screening, she developed two pancreatic islet cell tumors and a premalignant renal cyst. CONCLUSIONS Clinical and genetic screening for VHL in this family had a significant impact on surgical management by detecting early-stage islet cell tumors or pheochromocytomas. Furthermore, we conclude that the preponderance of pancreatic islet cell tumors in this family cannot be explained by a strict genotype-phenotype correlation. This suggests that additional genetic abnormalities, possibly on chromosome 3p where the VHL gene is located, may be responsible for the variety of VHL-associated neoplasms.
Collapse
Affiliation(s)
- S A Curley
- Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | |
Collapse
|
209
|
Atuk NO, Stolle C, Owen JA, Carpenter JT, Vance ML. Pheochromocytoma in von Hippel-Lindau disease: clinical presentation and mutation analysis in a large, multigenerational kindred. J Clin Endocrinol Metab 1998; 83:117-20. [PMID: 9435426 DOI: 10.1210/jcem.83.1.4479] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The clinical presentation and characterization of the mutation in members of a large kindred with von Hippel-Lindau disease (VHLD) and pheochromocytoma were examined. Twenty-five proven cases of VHLD occurring in four generations of a large kindred have been followed since 1964, and pheochromocytoma has occurred in 17. Symptoms of pheochromocytoma developed at an early age, on average at 12.5 +/- 1.3 yr, and definitive diagnosis and treatment of pheochromocytoma occurred at 19.9 +/- 2.6 yr. Significantly higher urine catecholamine concentrations were observed in younger patients than in older ones. Mutation analysis was performed in 14 family members, and a new mutation in the VHLD gene was identified in 11; this mutation is a G to T change at nucleotide 658 that results in the substitution of a serine for an alanine residue at position 149 of the polypeptide chain. Seven of the 11 patients with the mutation have VHLD; four, all 10 yr old or less, are asymptomatic and have no evidence of disease, but are at high risk for developing VHLD. These children are being followed closely for clinical and biochemical manifestations. The characterization of this new mutation has permitted identification of family members who are likely to develop VHLD.
Collapse
Affiliation(s)
- N O Atuk
- Department of Internal Medicine, University of Virginia Health Sciences Center, Charlottesville 22908, USA
| | | | | | | | | |
Collapse
|
210
|
Abstract
von Hippel-Lindau disease is a hereditary cancer syndrome characterized by the development of vascular tumors of the central nervous system and retina, clear cell renal carcinomas, pheochromocytomas, pancreatic islet cell tumors, endolymphatic sac tumors, and benign cysts affecting a variety of organs. VHL disease is caused by germline mutations of the von Hippel-Lindau tumor suppressor gene located on chromosome 3p25. Tumor development in this setting is due to inactivation or loss of the remaining wild-type allele in a susceptible cell. The highly vascular nature of VHL-associated neoplasms can be understood in light of the recent finding that the VHL gene product (pVHL) inhibits the accumulation of hypoxia-inducible mRNAs, such as the mRNA encoding vascular endothelial growth factor (VEGF), under normoxic conditions. This property of pVHL appears to be linked to its ability to bind to complexes containing elongin B, elongin C, and cullin 2 (Cul2). Elongin C and Cul2, based on their homology with Skp1 and Cdc53, respectively, are suspected of targeting certain proteins for covalent modification with ubiquitin and hence for degradation. One model, which remains to be tested, is that the binding of pVHL to elongins B/C and Cul2 affects the ubiquitination of RNA-binding proteins that regulate the stability of hypoxia-inducible mRNAs.
Collapse
Affiliation(s)
- E R Maher
- Division of Medical Genetics, University of Birmingham, Birmingham Women's Hospital, UK
| | | |
Collapse
|
211
|
Girelli R, Bassi C, Falconi M, De Santis L, Bonora A, Caldiron E, Sartori N, Salvia R, Briani G, Pederzoli P. Pancreatic cystic manifestations in von Hippel-Lindau disease. INTERNATIONAL JOURNAL OF PANCREATOLOGY : OFFICIAL JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PANCREATOLOGY 1997; 22:101-9. [PMID: 9387031 DOI: 10.1007/bf02787467] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
CONCLUSION In view of the frequent absence of symptoms related to pancreatic lesions, screening tests for VHL should always include assessment of the pancreas and, considering the frequency of polycystic manifestations, VHL should always be borne in mind in the differential diagnosis of multiple pancreatic cysts, especially when occurring in young patients and in the absence of a positive history of pancreatic disease. BACKGROUND Von Hippel-Lindau disease (VHL) is a hereditary disease transmitted with an autosomal dominant character and characterized by hemangioblastomas of the central nervous system and retina, renal tumors and cysts, and pheochromocytoma. Pancreatic manifestations of VHL are reported in the literature with incidences ranging from 16 to 29% of cases and consist mainly in cystadenomas of the serous type and in multiple cystic lesions, often with complete replacement of the gland. METHODS AND RESULTS We report five cases of VHL with a polycystic pancreas as the main or only manifestation, all devoid of symptoms related to involvement of the pancreas, who were referred to our Pancreatic Surgery center with diagnoses of multiple pancreatic pseudocysts of undefined origin.
Collapse
Affiliation(s)
- R Girelli
- Surgical Department, Borgo Roma University Hospital, University of Verona, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
212
|
Bakshi R, Mechtler LL, Patel MJ, Lindsay BD, Messinger S, Gibbons KJ. Spinal leptomeningeal hemangioblastomatosis in von Hippel-Lindau disease: magnetic resonance and pathological findings. J Neuroimaging 1997; 7:242-4. [PMID: 9344008 DOI: 10.1111/jon199774242] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
A 55-year-old man with von Hippel-Lindau disease presented with quadriparesis. Multiple enhancing cervical and thoracic spinal masses were seen on magnetic resonance imaging (MRI). A rim of diffuse, nodular enhancement linking all of the discrete masses was apparent on the surface of the cervical and thoracic regions of the cord. Surgical exploration revealed multiple extramedullary-intradural and intramedullary masses, extending to and infiltrating the cord; the leptomeninges contained numerous small tumor seeds at several levels. The excised spinal masses were diagnosed as capillary hemangioblastomas, which infiltrated the pia mater. Diffuse, intense, spinal leptomeningeal enhancement on MRI associated with multiple hemangioblastomas has not been previously reported and may be referred to as spinal "leptomeningeal hemangioblastomatosis."
Collapse
Affiliation(s)
- R Bakshi
- Dent Neurologic Institute, Millard Fillmore Health System, Department of Neurology, University of Buffalo, State University of New York Medicine and Biomedical Sciences, USA
| | | | | | | | | | | |
Collapse
|
213
|
Georg AE, Lunsford LD, Kondziolka D, Flickinger JC, Maitz A. Hemangioblastoma of the posterior fossa. The role of multimodality treatment. ARQUIVOS DE NEURO-PSIQUIATRIA 1997; 55:278-86. [PMID: 9629388 DOI: 10.1590/s0004-282x1997000200016] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The authors made a review of a series of patients with hemangioblastomas of the posterior fossa treated between 1973 and 1993. A total of 32 patients were analyzed with 24 patients receiving resection, 8 patients receiving radiosurgery and 2 patients receiving conventional radiotherapy. The mortality in the patients with a resection was considered acceptable with 2 deaths (8%) and with a morbidity of 3 patients (12.5%). A review of the literature suggests that conventional radiotherapy with high doses (45-60 Gy) may have a role in the post-operative control of hemangioblastomas and in some cases could be employed even before the resection in order to facilitate the surgery. The radiosurgical treatment is regarded like adjuvant. Poor results were obtained with radiosurgery in large tumors where low doses (less than 20 Gy) were used. Because of the rarity and complexity of these tumors, mainly when associated with von Hippel-Lindau disease, a multicenter study could be useful with the assessment of the optimal utilization and combination of these treatment modalities.
Collapse
Affiliation(s)
- A E Georg
- Serviço de Neurologia, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahiã (UFBA), Salvador, Brasil
| | | | | | | | | |
Collapse
|
214
|
Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16:68-73. [PMID: 9140397 DOI: 10.1038/ng0597-68] [Citation(s) in RCA: 1098] [Impact Index Per Article: 40.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Hereditary papillary renal carcinoma (HPRC) is a recently recognized form of inherited kidney cancer characterized by a predisposition to develop multiple, bilateral papillary renal tumours. The pattern of inheritance of HPRC is consistent with autosomal dominant transmission with reduced penetrance. HPRC is histologically and genetically distinct from two other causes of inherited renal carcinoma, von Hippel-Lindau disease (VHL) and the chromosome translocation (3;8). Malignant papillary renal carcinomas are characterized by trisomy of chromosomes 7, 16 and 17, and in men, by loss of the Y chromosome. Inherited and sporadic clear cell renal carcinomas are characterized by inactivation of both copies of the VHL gene by mutation, and/or by hypermethylation. We found that the HPRC gene was located at chromosome 7q31.1-34 in a 27-centimorgan (cM) interval between D7S496 and D7S1837. We identified missense mutations located in the tyrosine kinase domain of the MET gene in the germline of affected members of HPRC families and in a subset of sporadic papillary renal carcinomas. Three mutations in the MET gene are located in codons that are homologous to those in c-kit and RET, proto-oncogenes that are targets of naturally-occurring mutations. The results suggest that missense mutations located in the MET proto-oncogene lead to constitutive activation of the MET protein and papillary renal carcinomas.
Collapse
Affiliation(s)
- L Schmidt
- Intramural Research Support Program, SAIC Frederick, MD, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
215
|
Tibbs RE, Bowles AP, Raila FA, Fratkin JD, Hutchins JB. Should endolymphatic sac tumors be considered part of the von Hippel-Lindau complex? Pathology case report. Neurosurgery 1997; 40:848-55; discussion 855. [PMID: 9092862 DOI: 10.1097/00006123-199704000-00040] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
OBJECTIVE Von Hippel-Lindau (vHL) disease is an inherited disorder characterized by numerous cystic and solid neoplasms. Because of the recent identification of the vHL gene, other investigators have demonstrated genetic mutations in this gene in several of the neoplasms associated with the disease. We describe a patient with an endolymphatic sac (ELS) tumor and vHL disease. The purpose of this study was to identify a similar genetic mutation within the vHL gene of the ELS tumor. METHODS Using the patient's archival pathological slides, neoplastic cells were microdissected to yield a purely neoplastic cell population. The deoxyribonucleic acid of these cells was then extracted and amplified via polymerase chain reaction. After sufficient amplification, the specimen was analyzed on a single-strand conformation polymorphism gel system to detect putative changes in the base sequence. RESULTS Single-strand conformation polymorphism gel system analysis yielded two bands representing the two single strands of deoxyribonucleic acid that were amplified. The upper band of the specimen was shifted down (compared with controls), representing a conformational change as a result of genetic mutation. CONCLUSION ELS tumors are uncommon, and, to our knowledge, only seven cases associated with vHL disease have been reported in the literature. Although this association has been previously mentioned, no definitive studies have linked the two together. We report the eighth case of ELS tumor and vHL disease. We have demonstrated through molecular biological techniques, that, in our patient's tumor, a genetic mutation occurred, and that this mutation is similar to mutations previously reported in other neoplasms associated with vHL. We therefore suggest that ELS tumors be considered among the neoplasms associated with vHL.
Collapse
Affiliation(s)
- R E Tibbs
- Department of Neurosurgery, University of Mississippi Medical Center, Jackson 39216, USA
| | | | | | | | | |
Collapse
|
216
|
Corless CL, Kibel AS, Iliopoulos O, Kaelin WG. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol 1997; 28:459-64. [PMID: 9104946 DOI: 10.1016/s0046-8177(97)90035-6] [Citation(s) in RCA: 88] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Alterations in the von Hippel-Lindau (VHL) gene are correlated with a diverse group of neoplasms including hemangioblastoma, clear cell renal carcinoma (RCC), and pheochromocytoma. Molecular genetic studies suggest that VHL is a tumor-suppressor gene; correspondingly, reintroduction of a VHL complementary DNA (cDNA) into RCC cells inhibits their ability to form tumors in nude mice. Recently, it was discovered that the VHL gene product (pVHL) binds to two subunits of the transcription elongation complex Elongin (SIII), resulting in decreased activity of this complex in vitro. It is proposed that pVHL functions in vivo as a negative regulator of transcription elongation; however, the intracellular localization of pVHL has not been clearly delineated. Epitope-tagged pVHL has been observed in either the nucleus or the cytoplasm of cultured cells, depending on the density of the cell culture. In this article, the cellular localization of pVHL in normal and neoplastic human tissues is documented using three different monoclonal antibodies. Strong expression of pVHL was observed in the epithelial cells of all organs examined, particularly in renal tubules, and was exclusively cytoplasmic. Lesser degrees of staining, also cytoplasmic, were observed in other cell types. A variety of carcinomas (lung, prostate, colon, breast, bladder, and thyroid) showed strong cytoplasmic staining for pVHL including four of five sporadic clear cell RCC. Of the nonepithelial neoplasms examined, only one tumor, an embryonal rhabdomyosarcoma, failed to stain for pVHL. The findings establish wide-spread expression of VHL at the protein level and provide strong evidence that most, if not all, pVHL is localized to the cytoplasm of cells in vivo.
Collapse
Affiliation(s)
- C L Corless
- Department of Pathology, Oregon Health Sciences University, Portland, USA
| | | | | | | |
Collapse
|
217
|
|
218
|
Decker HJ, Weidt EJ, Brieger J. The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis. CANCER GENETICS AND CYTOGENETICS 1997; 93:74-83. [PMID: 9062583 DOI: 10.1016/s0165-4608(96)00296-8] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The von Hippel-Lindau (VHL) disease is an inherited tumor susceptibility syndrome featuring a high variety of benign and malignant tumors. The gene has been localized and cloned at 3p25-26. Recent functional analysis defined the VHL gene product as an inhibitor of the transcription elongation process. Its possible involvement in the vascularization process may explain the histologic features of VHL tumors providing insight into basic mechanism of tumorigenesis. Direct genetic testing is available for patients affected with VHL. Seventy to eighty percent of the germline mutations expected could be detected. As first geno/phenotype correlations have been established, we are now beginning to understand the diversity of this fascinating disease at the molecular level. As mutational analysis proved to be of striking prognostic significance, gene testing became an important tool for the management of the disease. The VHL gene was also found to be responsible for tumorigenesis in the corresponding sporadic tumors, especially in the clear cell type of renal cell carcinomas. The understanding of the normal and disturbed function of the VHL gene product will enable us to develop treatment strategies based on and targeted at the molecular cause of the disease. In this review we summarize the current knowledge about genetics, clinics, and function of VHL.
Collapse
Affiliation(s)
- H J Decker
- Department of Hematology and Oncology, Johannes-Gutenberg University, Mainz, Germany
| | | | | |
Collapse
|
219
|
Chambers TP, Fishman EK, Hruban RH. Pancreatic metastases from renal cell carcinoma in von Hippel-Lindau disease. Clin Imaging 1997; 21:40-2. [PMID: 9117930 DOI: 10.1016/0899-7071(95)00066-6] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
von Hippel-Lindau (VHL) disease is an unusual inherited chromosomal dominant disease characterized by CNS hemangioblastomas and visceral neoplasms. Multiple abnormalities may involve the abdomen including pathology in the liver, pancreas, kidneys, and adrenal glands. The present case report describes a patient with renal cell carcinoma in von Hippel-Lindau disease. What was most unusual about this case was that the patient also developed pancreatic masses that were metastatic disease from renal cell carcinoma.
Collapse
Affiliation(s)
- T P Chambers
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD, USA
| | | | | |
Collapse
|
220
|
Chen F, Slife L, Kishida T, Mulvihill J, Tisherman SE, Zbar B. Genotype-phenotype correlation in von Hippel-Lindau disease: identification of a mutation associated with VHL type 2A. J Med Genet 1996; 33:716-7. [PMID: 8863170 PMCID: PMC1050712 DOI: 10.1136/jmg.33.8.716] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
A family with von Hippel-Lindau disease (VHL) type 2A has been shown to have a T to C missense mutation at nucleotide 547 of the VHL gene. This gives further support for the proposal to associate the 547 T to C mutation with phenotype VHL 2A.
Collapse
Affiliation(s)
- F Chen
- Science Applications International Corp, Frederick, MD 21702, USA
| | | | | | | | | | | |
Collapse
|
221
|
Decker HJ, Neuhaus C, Jauch A, Speicher M, Ried T, Bujard M, Brauch H, Störkel S, Stöckle M, Seliger B, Huber C. Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation. A combined genetic study, including cytogenetics, PCR/SSCP, FISH, and CGH. Hum Genet 1996; 97:770-6. [PMID: 8641695 DOI: 10.1007/bf02346188] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
von Hippel-Lindau (VHL) disease is a pleiotropic disorder featuring a variety of malignant and benign tumors of the eye, central nervous system, kidney, and adrenal gland. Recently the VHL gene has been identified in the chromosomal region 3p25-26. Prognosis and successful management of VHL patients and their descendants depend on unambiguous diagnosis. Due to recurrent hemangioblastomas, a29-year-old patient without familial history of VHL disease was diagnosed to be at risk for the disease. Histopathological examination of a small renal mass identified a clear cell tumor with a G1 grading. Genetic characterization of the germline and of the renal tumor was performed. Polymerase chain reaction/single strand conformation polymorphism (PCR/SSCP) analysis with primers from the VHL gene identified a deletion of a single nucleotide in exon 2 in the patient's germline and in the tumor, but not in the DNA of his parents. This deletion therefore must be a de novo mutation. Comparative genome hybridization (CGH) and fluorescence in situ hybridization (FISH) analysis of the G1 tumor with differentially labelled yeast artifical chromosome (YAC) clones showed loss of 3p and of the 3p26 signals, respectively. In conclusion, we identified a de novo germline mutation in the VHL gene of a young patient and a somatic chromosome 3p loss at the homologous chromosome 3 in his renal tumor. Our results suggest a recessive mode of inactivation of the VHL gene, providing solid evidence for its tumor-suppressor gene characteristics. Our data show the diagnostic potential of genetic testing, especially in patients without VHL family history. Furthermore, the findings of homozygous inactivation of the VHL gene in a G1 tumor support the notion that the inactivation of the VHL gene is an early event in tumorigenesis of renal cell carcinoma.
Collapse
Affiliation(s)
- H J Decker
- Department of Haematology and Oncology, Johannes-Gutenberg University of Mainz, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
222
|
Patrice SJ, Sneed PK, Flickinger JC, Shrieve DC, Pollock BE, Alexander E, Larson DA, Kondziolka DS, Gutin PH, Wara WM, McDermott MW, Lunsford LD, Loeffler JS. Radiosurgery for hemangioblastoma: results of a multiinstitutional experience. Int J Radiat Oncol Biol Phys 1996; 35:493-9. [PMID: 8655372 DOI: 10.1016/s0360-3016(96)80011-3] [Citation(s) in RCA: 78] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
PURPOSE Between June 1988 and June 1994. 38 hemangioblastomas were treated with stereotactic radiosurgery (SR) at three SR centers to evaluate the efficacy and potential toxicity of this therapeutic modality as an adjuvant or alternative treatment to surgical resection. METHODS AND MATERIALS SR was performed using either a 201-cobalt source unit or a dedicated SR linear accelerator. Of the 18 primary tumors treated, 16 had no prior history of surgical resection and were treated definitively with SR and two primary lesions were subtotally resected and subsequently treated with SR. Twenty lesions were treated with SR after prior surgical failure (17 tumors) or failure after prior surgery and conventional radiotherapy (three tumors). Eight patients were treated with SR for multifocal disease (total, 24 known tumors). SR tumor volumes measured 0.05 to 12 cc (median: 0.97 cc). Minimum tumor doses ranged from 12 to 20 Gy (median: 15.5 Gy). RESULTS Median follow-up from the time of SR was 24.5 months (range: 6-77 months). The 2-year actuarial over-all survival was 88 +/- 15% (95% confidence interval). Two-year actuarial freedom from progression was 86 +/- 12% (95% confidence interval). The median tumor volume of the lesions that failed to be controlled by SR was 7.85 cc (range: 3.20-10.53 cc) compared to 0.67 cc (range: 0.05-12 cc) for controlled lesions (p - 0.0023). The lesions that failed to be controlled by SR received a median minimum tumor dose of 14 Gy (range: 13-17 Gy) compared to 16 Gy (range: 12-20 Gy) for controlled lesions (p = 0.0239). Seventy-eight percent of the surviving patients remained neurologically stable or clinically improved. There were no significant permanent complications directly attributable to SR. CONCLUSIONS This report documents the largest experience in the literature of the use of SR in the treatment of hemangioblastoma. We conclude that SR: (a) controls the majority of primary and recurrent hemangioblastomas; (b) offers the ability to treat multiple lesions in a single treatment session, which is particularly important for patients with Von Hippel-Lindau Syndrome; and that (c) better control rates are associated with higher doses and smaller tumor volumes.
Collapse
Affiliation(s)
- S J Patrice
- Harvard Joint Center for Radiation Therapy, Brigham and Women's Hospital, Boston, MA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
223
|
Kanno H, Shuin T, Kondo K, Ito S, Hosaka M, Torigoe S, Fujii S, Tanaka Y, Yamamoto I, Kim I, Yao M. Molecular genetic diagnosis of von Hippel-Lindau disease: analysis of five Japanese families. Jpn J Cancer Res 1996; 87:423-8. [PMID: 8641976 PMCID: PMC5921130 DOI: 10.1111/j.1349-7006.1996.tb00240.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
We analyzed deoxyribonucleic acids from blood samples of five Japanese von Hippel-Lindau (VHL) disease families (three familial cases, two new mutations) for the presence of VHL gene mutations by single-strand conformational polymorphism analysis and direct sequencing. Four of the five families showed germ line mutations in VHL gene, comprising 2 missense mutations, 1 deletion, and 1 splice-site mutation. Two families had VHL gene mutations at exon 1; 1 family at exon 3; and 1 family at the splice-site adjacent to exon 3. Presymptomatic patients were accurately diagnosed by these methods. However, one family did not show a VHL gene mutation in the germ line but showed a somatic mutation at exon 2 in the hemangioblastoma tissue. The consequence of the somatic mutation was a microdeletion leading to a frameshift mutation. Our study is the first report of VHL gene analyses of Japanese VHL disease families, and suggests that not only germ line mutation, but also somatic mutation can lead to development of a tumor associated with the VHL disease.
Collapse
Affiliation(s)
- H Kanno
- Department of Neurosurgery, Yokohama City University School of Medicine, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
224
|
Kelley LC, Crowell WA, Puette M, Langheinrich KA, Self AD. A retrospective study of multicentric bovine renal cell tumors. Vet Pathol 1996; 33:133-41. [PMID: 8801706 DOI: 10.1177/030098589603300202] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Tissues from twenty mature cows with primary renal cell tumors were submitted over an 11-year period because of gross lesions detected during routine slaughter and inspection. Tumors visualized grossly were multiple and bilateral in seven cattle, multiple within one kidney in four cattle, and solitary in nine cattle. The tumors were primarily cortical, yellow-orange to tan, proliferative, well circumscribed, and extended above the capsular surface of the kidney. Tumors were microscopically multiple even when grossly described as solitary lesions, except in one cow. Twelve tumors (60%) were microscopically multiple in one kidney, seven tumors (35%) were multiple and bilateral, and only one cow (5%) exhibited extrarenal metastasis. Tumors from nineteen cows were composed of eosinophilic granular epithelial cells; tumors from one cow were clear cell type. Each tumor contained several histologic patterns. Corpora amylacea, proteinaceous secretions, and hemosiderin were characteristic findings in bovine renal cell carcinoma. All 20 cows with renal cell tumors exhibited positive immunoreactivity to uromodulin (Tamm-Horsfall protein).
Collapse
Affiliation(s)
- L C Kelley
- Pathology Division, Eastern Laboratory, US Department of Agriculture, Athens, GA, USA
| | | | | | | | | |
Collapse
|
225
|
Maddock IR, Moran A, Maher ER, Teare MD, Norman A, Payne SJ, Whitehouse R, Dodd C, Lavin M, Hartley N, Super M, Evans DG. A genetic register for von Hippel-Lindau disease. J Med Genet 1996; 33:120-7. [PMID: 8929948 PMCID: PMC1051837 DOI: 10.1136/jmg.33.2.120] [Citation(s) in RCA: 175] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
A genetic register for von Hippel-Lindau disease was set up in the north west of England in 1990. Population statistics, clinical features, age at onset, and survival of 83 people affected with von Hippel-Lindau (VHL) disease were studied. In addition, the effectiveness of the screening programme used and the occurrence of central nervous system haemangioblastomas in the general population were examined. The diagnostic point prevalence of heterozygotes in the North Western Region was 1 center dot 18/100 000 (1/85 000) people, with an estimated birth incidence of 2 center dot 20/100 000 (1/45 500) live births. The mutation rate was estimated directly to be 1 center dot 4 x 10(-6)/gene/generation (1/714 200). The mean age at onset of first symptoms was 26 center dot 25 years, with cerebellar haemangioblastoma being the most common presenting manifestation (34 center dot 9% of cases). The mean age at diagnosis of VHL disease was 30 center dot 87 years. Overall, 50 patients (60 center dot 2%) developed a cerebellar haemangioblastoma, 34 (41 center dot 0%) a retinal angioma, 21 (25 center dot 3%) a renal cell carcinoma, 12 (14 center dot 5%) a spinal haemangioblastoma, and 12 (14 center dot 5%) a phaeochromocytoma. Mean age at diagnosis of renal cell carcinoma (38 center dot 9 years) was significantly higher than that for cerebellar haemangioblastoma (30 center dot 0 years) and retinal angioma (21.1 years). Mean age at death was 40 center dot 9 years with cerebellar haemangioblastoma being the most common cause (47 center dot 7% of deaths). A total of 65 VHL manifestations were diagnosed asymptomatically following appropriate clinical and radiological screening tests, and failure to detect manifestations of VHL disease in spite of appropriate screening occurred on only two occasions. The use of DNA linkage analysis and direct mutation testing reduced the personal risk of carrying the VHL gene to below 1% in 14 people. In addition to the 83 clinically affected subjects, three obligate carriers who were considered to be lesion free in spite of extensive screening tests were identified. Fourteen percent of all CNS haemangioblastomas on the regionally based Cancer Registry were found to occur as part of VHL disease, but investigations for VHL in apparently sporadic disease appeared to be limited.
Collapse
Affiliation(s)
- I R Maddock
- Department of Medical Genetics, St Mary's Hospital, Manchester, UK
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
226
|
Ercan M, Kahraman S, Başgül E, Aypar U. Anaesthetic management of a patient with von Hippel-Lindau disease: a combination of bilateral phaeochromocytoma and spinal cord haemangioblastoma. Eur J Anaesthesiol 1996; 13:81-3. [PMID: 8829941 DOI: 10.1097/00003643-199601000-00014] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The management of patients with Hippel-Lindau disease is discussed and illustrated using a case report. The importance of associated phaeochromocytoma and spinal involvement is stressed.
Collapse
Affiliation(s)
- M Ercan
- Hacettepe University, Department of Anaesthesiology and Reanimation, Ankara, Turkey
| | | | | | | |
Collapse
|
227
|
Humphrey JS, Klausner RD, Linehan WM. Von Hippel-Lindau syndrome: hereditary cancer arising from inherited mutations of the VHL tumor suppressor gene. Cancer Treat Res 1996; 88:13-39. [PMID: 9239471 DOI: 10.1007/978-1-4615-6343-3_2] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|
228
|
Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM, Crossey PA, Webster AR, Affara NA, Ferguson-Smith MA, Brauch H, Glavac D, Neumann HP, Tisherman S, Mulvihill JJ, Gross DJ, Shuin T, Whaley J, Seizinger B, Kley N, Olschwang S, Boisson C, Richard S, Lips CH, Lerman M. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 1996; 8:348-57. [PMID: 8956040 DOI: 10.1002/(sici)1098-1004(1996)8:4<348::aid-humu8>3.0.co;2-3] [Citation(s) in RCA: 298] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Germline mutation analysis was performed in 469 VHL families from North America, Europe, and Japan. Germline mutations were identified in 300/469 (63%) of the families tested; 137 distinct intragenic germline mutations were detected. Most of the germline VHL mutations (124/137) occurred in 1-2 families; a few occured in four or more families. The common germline VHL mutations were: delPhe76, Asn78Ser, Arg161Stop, Arg167Gln, Arg167Trp, and Leu178Pro. In this large series, it was possible to compare the effects of identical germline mutations in different populations. Germline VHL mutations produced similar cancer phenotypes in Caucasian and Japanese VHL families. Germline VHL mutations were identified that produced three distinct cancer phenotypes: (1) renal carcinoma without pheochromocytoma, (2) renal carcinoma with pheochromocytoma, and (3) pheochromocytoma alone. The catalog of VHL germline mutations with phenotype information should be useful for diagnostic and prognostic studies of VHL and for studies of genotype-phenotype correlations in VHL.
Collapse
Affiliation(s)
- B Zbar
- Laboratory of Immunobiology, Biological Carcinogenesis and Development Program, SAIC Frederick, Maryland, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
229
|
Gilcrease MZ, Schmidt L, Zbar B, Truong L, Rutledge M, Wheeler TM. Somatic von Hippel-Lindau mutation in clear cell papillary cystadenoma of the epididymis. Hum Pathol 1995; 26:1341-6. [PMID: 8522307 DOI: 10.1016/0046-8177(95)90299-6] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Papillary cystadenoma of the epididymis is an uncommon benign lesion that may occur sporadically or as a manifestation of von Hippel-Lindau (VHL) disease. Neither immunohistochemical studies nor molecular genetic analyses of the VHL gene have been reported previously for this lesion. The authors describe two cases of clear cell papillary cystadenoma of the epididymis, both of which were initially confused with metastatic renal cell carcinoma. Both lesions showed positive immunohistochemical staining for low and intermediate molecular weight keratins (Cam 5.2 and AE1/AE3), EMA, vimentin, alpha 1-antitrypsin, and alpha 1-antichymotrypsin. Each was negative for CEA. Because clear cell papillary cystadenoma is similar to renal cell carcinoma histologically, and because both occur as components of the von Hippel-Lindau disease complex, the authors analyzed both cases for the presence of mutations in the VHL gene. A somatic VHL gene mutation was detected in one of the two tumors by polymerase chain reaction followed by single-strand conformation polymorphism analysis. Direct sequencing revealed a cytosine to thymine transition at nucleotide 694, resulting in the replacement of an arginine with a stop codon after the sixth amino acid of exon 3. As the VHL gene is believed to function as a tumor suppressor gene, VHL gene mutations may play a role in the initiation of tumorigenesis in sporadic cystadenomas of the epididymis.
Collapse
Affiliation(s)
- M Z Gilcrease
- Department of Pathology, Baylor College of Medicine, Houston, TX, USA
| | | | | | | | | | | |
Collapse
|
230
|
Bleggi-Torres LF, De Noranha L, Fillus Neto J, Telles JE, Madalozzo LE. Von Hippel-Lindau's disease: report of three cases and review of the literature. ARQUIVOS DE NEURO-PSIQUIATRIA 1995; 53:782-8. [PMID: 8729773 DOI: 10.1590/s0004-282x1995000500012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The authors present the autopsy findings of two related patients and the biopsy findings of a third member of the family. The oldest member was 34 years old at death and on postmortem examination he had haemangioblastomas in the retina, cerebellum, medulla and spinal cord. Other findings were renal cell carcinoma, phaechromocytoma, cysts of kidney and pancreas, hydromyelia and atypical meningiomas. His brother died when 30 years old. The autopsy revealed haemangioblastomas of cerebellum, renal cell carcinoma and a clear cell cystadenoma of epididymus. The third patient was the daughter of the first and presented with headache and dizziness. CT-scan showed a cerebellar haemangioblastoma. Epidemiological considerations on the commonest visceral and CNS lesions and a review of current diagnostic criteria are discussed.
Collapse
Affiliation(s)
- L F Bleggi-Torres
- Department of Pathology, Federal University of Paraná, Curitiba, Brazil
| | | | | | | | | |
Collapse
|
231
|
Kley N, Whaley J, Seizinger BR. Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function. Glia 1995; 15:297-307. [PMID: 8586465 DOI: 10.1002/glia.440150310] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Most of the genes for hereditary tumor syndromes cloned thus far have subsequently been shown to be mutated not only in the germlines and tumors from patients with the relatively rare inherited disease, but also in the much more common sporadic tumor counterparts in the general population. Thus, the isolation and functional characterization of genes associated with hereditary tumor syndromes have emerged as a major strategy to gain insights into some of the most fundamental mechanisms of tumorigenesis. The search for the genes causing two hereditary tumor syndromes of the nervous system, neurofibromatosis type 2 (NF2) and von Hippel-Lindau disease (VHL), has recently culminated in the cloning of both disease genes. This represents another successful application of the so-called positional cloning approach, i.e., the isolation of a hereditary disease gene with unknown function, based on the determination of its chromosomal location in the human genome. The gene for NF2, a syndrome typically associated with vestibular schwannomas and meningiomas, is homologous with a family of genes whose members appear to play an important role in bridging the cell membrane with the intracellular cytoskeleton, including moesin, ezrin, radixin, and protein 4.1. Recent mutation analyses have revealed that the NF2 tumor suppressor gene is frequently mutated not only in vestibular schwannomas and meningiomas from NF2 patients, but also in their sporadic counterparts, which represent approximately one-third of all human brain tumors. Furthermore, malignant human tumors seemingly unrelated to the NF2 syndrome, such as neural crest-derived malignant melanomas, as well as malignant mesotheliomas (a pleural mesoderm-derived tumor), have also been found to be frequently mutated or deleted in the NF2 locus, suggesting a broader role for the NF2 gene in the initiation and progression of human neoplasms. VHL is a rare tumor syndrome characterized by certain types of nervous system tumors (cerebellar and spinal hemangioblastomas as well as retinal angiomas), in conjunction with bilateral renal cell carcinomas and pheochromocytomas. Similar to NF2, recent genetic mutation studies have revealed that the VHL tumor suppressor gene is not only mutated in the hereditary tumors from VHL patients, but also in their sporadic counterparts. Importantly, the VHL gene represents the most frequently mutated cancer-related gene thus far identified in sporadic renal cell carcinoma. In contrast to most other hereditary cancer syndromes, however, VHL mutations are surprisingly specific for tumors typically associated with the VHL syndrome, and have not been detected in any other tumor type unrelated to VHL. The cloning and initial genetic characterization of the NF2 and VHL genes have now provided a rational basis for subsequent functional studies on the elucidation of the normal and tumor-associated cellular signaling pathways of these tumor suppressor genes.
Collapse
Affiliation(s)
- N Kley
- Department of Molecular Genetics, Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000, USA
| | | | | |
Collapse
|
232
|
Maher ER, Webster AR, Moore AT. Clinical features and molecular genetics of Von Hippel-Lindau disease. Ophthalmic Genet 1995; 16:79-84. [PMID: 8556282 DOI: 10.3109/13816819509059966] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Although familial cancer syndromes are rare, a knowledge of these disorders is relevant to both clinicians and basic scientists. This is exemplified by Von Hippel-Lindau (VHL) disease which is caused by germline mutations in the VHL tumour suppressor gene. This multisystem disorder provides a complex clinical problem for ophthalmologists and other specialists. In addition, recent advances in the molecular genetics of this disorder are providing novel insights into the molecular mechanisms of tumourigenesis in VHL disease and in more common nonfamilial neoplasms such as clear cell renal carcinoma and central nervous system haemangioblastoma. In this review, we describe the clinical manifestations (with particular reference to the ocular complications) and the molecular genetics of VHL disease.
Collapse
Affiliation(s)
- E R Maher
- Cambridge University Department of Pathology, UK
| | | | | |
Collapse
|
233
|
Abstract
The neurocutaneous diseases are a collection of more than 40 hereditary and spontaneously occurring disorders, many of which have prominent lesions involving the nervous system and skin. In this article, the classification of the neurocutaneous diseases is briefly reviewed, and the neuropathologic characteristics of four of these diseases (neurofibromatosis, tuberous sclerosis, von Hippel-Lindau disease, and Sturge-Weber disease) are summarized.
Collapse
Affiliation(s)
- J S Nelson
- Department of Pathology, Louisiana State University Medical Center, New Orleans 70112, USA
| |
Collapse
|
234
|
|
235
|
Affiliation(s)
- M Yao
- Department of Urology, Yokohama City University School of Medicine, Japan
| | | |
Collapse
|
236
|
Abstract
After a decade of intensive clinical and molecular genetic efforts the von Hippel-Lindau (VHL) gene was cloned in 1993. The open reading frame encodes the putative protein of 284 amino acids. A large number of different mutations have been identified so far, including single base mutations, deletions, rearrangements and more complex mutations. So far, in about 75% of the VHL families germline mutations were detected. Geno-phenotypic comparison has revealed specific mutations with distinct manifestation patterns. Not all of the 6 classical lesions (hemangioblastoma of the CNS, retinal angiomatosis, pancreatic cysts, renal cysts and carcinoma, pheochromocytoma and epididymal cystadenoma) are present in VHL families. Pedigrees with pheochromocytoma but without renal cancer in general have point mutations. These recent results provide insight in the pathogenesis of a multiorgan cancer susceptibility tumor suppressor gene and allow determination of carrier status.
Collapse
Affiliation(s)
- H P Neumann
- Department of Medicine, Albert-Ludwigs-University, Freiburg, Germany
| | | | | | | |
Collapse
|
237
|
Balcer LJ, Galetta SL, Curtis M, Maguire A, Judy K. von Hippel-Lindau disease manifesting as a chiasmal syndrome. Surv Ophthalmol 1995; 39:302-6. [PMID: 7725229 DOI: 10.1016/s0039-6257(05)80107-9] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
A 21-year-old woman presented with a two year history of progressive loss of vision in the left eye. Brain MRI revealed a supresellar mass felt to be most consistent with a meningioma. However, pathologic examination including special stains disclosed features characteristic of hemangioblastoma. Further evaluation established the diagnosis of von Hippel-Lindau disease by demonstrating retinal capillary hemangiomas, small renal and hepatic cysts, and cervico-medullary masses later confirmed to be hemangioblastomas. To date, no other family members have displayed features of this inherited syndrome.
Collapse
Affiliation(s)
- L J Balcer
- Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, USA
| | | | | | | | | |
Collapse
|
238
|
Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 1995; 5:66-75. [PMID: 7728151 DOI: 10.1002/humu.1380050109] [Citation(s) in RCA: 407] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
von Hippel-Lindau disease (VHL) is an inherited neoplastic disease characterized by a predisposition to develop retinal angiomas, central nervous system hemangioblastomas, renal cell carcinomas, pancreatic cysts, and pheochromocytomas. The VHL gene was recently isolated by positional cloning. The cDNA encodes 852 nucleotides in 3 exons. The VHL gene is unrelated to any known gene families. We identified germline mutations in 85/114 (75%) of VHL families. Clinical heterogeneity is a well-known feature of VHL. VHL families were classified into 2 types based on the presence or absence of pheochromocytoma. The types of mutations responsible for VHL without pheochromocytoma (VHL type 1) differed from those responsible for VHL with pheochromocytoma (VHL type 2). Fifty-six % of the mutations responsible for VHL type 1 were microdeletions/insertions, nonsense mutations, or deletions; 96% of the mutations responsible for VHL type 2 were missense mutations. Specific mutations in codon 238 accounted for 43% of the mutations responsible for VHL type 2. The mutations identified in these families will be useful in presymptomatic diagnosis. The identification of mutations associated with phenotypes contributes to the understanding of fundamental genetic mechanisms of VHL disease.
Collapse
Affiliation(s)
- F Chen
- Program Resources, Inc./DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
239
|
Nelson JB, Oyasu R, Dalton DP. The clinical and pathological manifestations of renal tumors in von Hippel-Lindau disease. J Urol 1994; 152:2221-6. [PMID: 7966714 DOI: 10.1016/s0022-5347(17)31646-4] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The protean nature of renal lesions in von Hippel-Lindau disease has made surgical management difficult. To develop a sensible surgical approach the pathological and clinical manifestations of renal involvement in von Hippel-Lindau disease patients were defined. A total of 87 lesions in 9 kidneys from 6 patients with von Hippel-Lindau disease was examined for size, presence of renal cell carcinoma, cystic or solid qualities and local invasion. There was no correlation between the size of the lesion and renal cell carcinoma. All 44 benign lesions were cystic, while 35% (15 of 43) of malignant lesions were cystic and 65% (28 of 43) were solid. All 9 locally invasive tumors were solid. The distribution of lesions in our patients was compared to the findings in 138 cases we collected from the literature. The 3 patterns of clinical presentation recognized were solitary, multiple and diffuse. We recommended that all lesions, cystic or solid, be excised at the time of nephron sparing surgery, with a wider margin for solid lesions, and that nephron sparing surgery should be reserved for patients with cystic and small solid lesions, with radical nephrectomy being preferred for patients with diffuse disease.
Collapse
Affiliation(s)
- J B Nelson
- Department of Urology, Northwestern University Medical School, Chicago, Illinois
| | | | | |
Collapse
|
240
|
Decker HJ, Klauck SM, Lawrence JB, McNeil J, Smith D, Gemmill RM, Sandberg AA, Neumann HH, Simon B, Green J. Cytogenetic and fluorescence in situ hybridization studies on sporadic and hereditary tumors associated with von Hippel-Lindau syndrome (VHL). CANCER GENETICS AND CYTOGENETICS 1994; 77:1-13. [PMID: 7923076 DOI: 10.1016/0165-4608(94)90141-4] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
We performed cytogenetic and fluorescence in situ hybridization (FISH) studies on 29 sporadic or familial tumors associated with von Hippel-Lindau [correction of Landau] disease. Four of five renal cell carcinomas with detectable alterations showed clones with chromosome 3 alterations. These changes led to loss of genetic material visible with cytogenetic resolution: either an unbalanced translocation involving 3p or loss of a whole homolog 3, resulting in monosomy of 3p. We have previously mapped the VHL gene to chromosomal region 3p25-p26. We applied FISH using the single copy probes cA233 and cA479, sequences close to the VHL gene, in a search for submicroscopic deletions of 3p. Use of FISH with differentially labeled probes indicated cA479 to be distal to cA233, but both were located within bands 3p25-26. FISH with single copy probes for interphase cytogenetics detected four subclones with deletions in the VHL region in 8/22 tumors, including four tumors which appeared cytogenetically normal. FISH proved to be a powerful tool in tumor genetic studies, especially helpful in detecting tumor subclones in benign and slowly growing tumors.
Collapse
Affiliation(s)
- H J Decker
- Molecular Neuro-Oncology Laboratory, Massachusetts General Hospital, Boston
| | | | | | | | | | | | | | | | | | | |
Collapse
|
241
|
Karsdorp N, Elderson A, Wittebol-Post D, Hené RJ, Vos J, Feldberg MA, van Gils AP, Jansen-Schillhorn van Veen JM, Vroom TM, Höppener JW. Von Hippel-Lindau disease: new strategies in early detection and treatment. Am J Med 1994; 97:158-68. [PMID: 8059782 DOI: 10.1016/0002-9343(94)90026-4] [Citation(s) in RCA: 53] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
UNLABELLED Von Hippel-Lindau disease is an autosomal dominant inherited disorder causing hemangioblastomas of the central nervous system (CNS), retinal hemangiomas, renal cell carcinomas, pheochromocytomas, pancreatic and liver cysts, and epididymal cystadenomas. PURPOSE Since 1976, we have periodically screened for the lesions in a large affected family and were able to evaluate new strategies in detection and treatment. PATIENTS AND METHODS A total of 23 individuals underwent the screening program. A multidisciplinary team of physicians was involved. RESULTS In 13 patients (7 females and 6 males), a total of 31 tumors was detected; hemangioblastoma of the CNS (9), retinal angioma (4), renal involvement (8), pheochromocytoma (4), pancreatic lesions (4), and liver lesions (2) were diagnosed by periodic family screening. On the basis of more than 10 years of experience and current literature, new criteria for diagnosis and treatment have been proposed. CONCLUSION The von Hippel-Lindau disease gene appears to be a tumor suppressor gene, and its absence or a defect in its structure is responsible for the predisposition to the disease. Tumor development depends on a somatic second mutation in the homologous allele. That means, in disease-gene carriers, tumor growth may begin at any age. Most of the lesions can be treated successfully when diagnosed in time. Periodic screening by a multidisciplinary team has to be continued lifelong.
Collapse
Affiliation(s)
- N Karsdorp
- Department of Internal Medicine, University Hospital Utrecht, The Netherlands
| | | | | | | | | | | | | | | | | | | |
Collapse
|
242
|
Abstract
OBJECTIVES To optimise radiological screening in von Hippel-Lindau disease (VHL) while minimising cost and morbidity. METHODS A model of VHL was based on retrospective studies, and Bayes's theorem used to calculate the probability of the gene's presence and the likelihood of further lesions in affected families. A six year follow up was conducted to test the validity of the model. RESULTS Follow up confirmed the accuracy and validity of the model. Posterior fossa haemangioblastomas occur in 79.2% of VHL cases, supratentorial, retinal and spinal haemangioblastomas in 6.9%, 42.8%, and 22.0%, phaeochromocytomas in 5.2%, and renal carcinomas in 14.5%. Population incidences are 1:15,700 live births (posterior fossa), 1:780,000 (supratentorial), and 1:116,000 (spinal). The birth rate of subjects with VHL is 1:43,000; new mutations occur in 1:178,000 live births. Penetrance is 90%; 40% present with multiple lesions and 6.4% die within two years after diagnosis. CONCLUSIONS For most patients presenting with a VHL-type lesion, with sufficient clinical and pedigree data, the presence or absence of the VHL gene, and the probability of further lesions occurring, can be assessed with a high degree of accuracy using the method described in this paper. Those cases in the non-VHL group do not require long term radiological follow up, nor do their relatives require radiological screening. Subjects in the VHL group should be screened for renal carcinoma indefinitely from the age of 20 years, and all clinically unaffected relatives should be screened genetically for the VHL gene. (Those found negative for the gene do not require further screening, but those found positive should be screened.)
Collapse
Affiliation(s)
- R W Harries
- Department of Radiology, Grimsby District General Hospital, United Kingdom
| |
Collapse
|
243
|
Zbar B, Tory K, Merino M, Schmidt L, Glenn G, Choyke P, Walther MM, Lerman M, Linehan WM. Hereditary papillary renal cell carcinoma. J Urol 1994; 151:561-6. [PMID: 8308957 DOI: 10.1016/s0022-5347(17)35015-2] [Citation(s) in RCA: 168] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
We describe a 3 generation family with members affected with papillary renal cell carcinoma, an uncommon histological type of renal cell carcinoma. Multiple tumors of varying size were present in both kidneys of affected family members. The disorder was not linked to polymorphic markers on chromosome 3p and there was no loss of heterozygosity at loci on 3p in renal tumors. The results suggest the presence of a renal cell carcinoma gene not located on 3p that predisposes to renal cell carcinoma with a distinct histological appearance. The inherited disorder in this family appears to be different from recognized hereditary cancer syndromes.
Collapse
Affiliation(s)
- B Zbar
- Program Resources Inc. (Division of Dynacorp Inc.), Frederick
| | | | | | | | | | | | | | | | | |
Collapse
|
244
|
Affiliation(s)
- E R Maher
- University of Cambridge, Addenbrooke's Hospital, U.K
| |
Collapse
|
245
|
Yao M, Latif F, Orcutt ML, Kuzmin I, Stackhouse T, Zhou FW, Tory K, Duh FM, Richards F, Maher E. von Hippel-Lindau disease: identification of deletion mutations by pulsed-field gel electrophoresis. Hum Genet 1993; 92:605-14. [PMID: 8262521 DOI: 10.1007/bf00420947] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Von Hippel-Lindau disease (VHL) is an inherited multisystem neoplastic disorder. We prepared a 2.5-megabase (Mb) restriction map of the region surrounding the VHL gene and identified and characterized overlapping deletions in three unrelated patients affected with VHL. The smallest nested deletion (100 kb) was located within a 510-kb NruI fragment detected by 19-63'. The rearrangements detected will be useful in isolating and evaluating candidate cDNAs for the VHL gene. The detailed physical map will be useful in studying the organization and structure of genes in the VHL region.
Collapse
Affiliation(s)
- M Yao
- Laboratory of Immunobiology, National Cancer Institute-Frederick Cancer Research and Development Center, MD 21702
| | | | | | | | | | | | | | | | | | | |
Collapse
|
246
|
Neumann HP, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, Volk B, Kirste G. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993; 329:1531-8. [PMID: 8105382 DOI: 10.1056/nejm199311183292103] [Citation(s) in RCA: 249] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
BACKGROUND Pheochromocytoma is a feature of two disorders with an autosomal dominant pattern of inheritance--multiple endocrine neoplasia type 2 (MEN-2) (with medullary thyroid carcinoma and hyperparathyroidism) and von Hippel-Lindau disease (with angioma of the retina, hemangioblastoma of the central nervous system, renal-cell carcinoma, pancreatic cysts, and epididymal cystadenoma). The frequency of these syndromes in patients with pheochromocytoma is not known. METHODS In an unselected group of patients with pheochromocytoma, we performed pentagastrin tests, parathyroid hormone assays, computed tomography (CT) or magnetic resonance imaging (MRI) of the brain, ophthalmoscopy, CT imaging of the abdomen, and ultrasonography of the testes. We also screened members of families with MEN-2 or von Hippel-Lindau disease for pheochromocytoma by measuring plasma and urine catecholamines and plasma chromogranin A and by performing abdominal ultrasonography, CT and MRI, and metaiodobenzylguanidine scintigraphy. RESULTS Nineteen of 82 unselected patients with pheochromocytomas (23 percent) were carriers of familial disorders; 19 percent had von Hippel-Lindau disease and 4 percent had MEN-2. Prospectively, in 36 of 79 subjects at risk for pheochromocytoma (46 percent), 42 unsuspected pheochromocytomas were found. Overall, there were 130 patients with 185 pheochromocytomas; 43 had von Hippel-Lindau disease, 24 had MEN-2, and 63 had sporadic tumors. The patients with familial and those with sporadic pheochromocytomas differed in mean age at diagnosis (32 vs. 46 years, P < 0.001), multifocal localization (55 vs. 8 percent, P < 0.001), and cancer (0 vs. 11 percent, P = 0.005); but not in the frequency of extraadrenal tumors (24 vs. 16 percent). Thirty-eight percent of carriers of von Hippel-Lindau disease and 24 percent of carriers of MEN-2 had pheochromocytoma as the only manifestation of their syndrome. CONCLUSIONS All patients with pheochromocytomas should be screened for MEN-2 and von Hippel-Lindau disease to avert further morbidity and mortality in the patients and their families. All patients in families with MEN-2 or von Hippel-Lindau disease should be screened for pheochromocytoma, even if they are asymptomatic.
Collapse
Affiliation(s)
- H P Neumann
- Department of Medicine, Albert-Ludwigs-Universität, Freiburg, Germany
| | | | | | | | | | | | | | | |
Collapse
|
247
|
Szymanski SC, Hummerich H, Latif F, Lerman MI, Röhrborn G, Schröder E. Long range restriction map of the von Hippel-Lindau gene region on human chromosome 3p. Hum Genet 1993; 92:282-8. [PMID: 8406436 DOI: 10.1007/bf00244473] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Von Hippel-Lindau disease is a heritable tumour syndrome caused by the loss of the function of a tumour suppressor gene on the short arm of human chromosome 3. The interval RAF1-D3S18 (3p25-3p26) has been identified by genetic linkage studies to harbour the von Hippel-Lindau gene. We have constructed a long range restriction map of this region and have succeeded in demonstrating the physical linkage of loci D3S726 (DNA probe LIB31-38), D3S18 (c-LIB-1, L162E5), D3S601 (LIB19-63) and D3S587 (LIB12-48). Since multipoint analysis has located D3S601 proximal to D3S726, the physical map should be oriented with D3S726 towards the telomere. The order and distances of probes within the von Hippel-Lindau gene region is as follows: telomere--LIB31-38--(< 280 kb)--c-LIB-1--(overlapping)--L162E5--(900-1600 kb)--(LIB19-63, LIB12-48)--centromere. In tissues that included blood, semen and Epstein-Barr-virus-transformed lymphocytes, we detected a putative CpG island flanking D3S18.
Collapse
Affiliation(s)
- S C Szymanski
- Department of Internal Medicine (Cancer Research), University of Essen Medical School, Germany
| | | | | | | | | | | |
Collapse
|
248
|
Symon L, Murota T, Pell M, Bordi L. Surgical management of haemangioblastoma of the posterior fossa. Acta Neurochir (Wien) 1993; 120:103-10. [PMID: 8460560 DOI: 10.1007/bf02112026] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Fifty-one cases of posterior fossa haemangioblastoma have been seen in our department over a period of 23 years. Seven cases were associated with spinal cord lesions and one with a supratentorial lesion. There were 22 cases of Lindau's disease (43%). The onset was earlier and recurrences commoner than in isolated cases. In 10 cases the development of new tumours in different parts of the central nervous system (CNS) required re-operation, demonstrating the multicentric nature of this disease. The majority of the tumours occupying the fourth ventricle or medulla oblongata (8 cases) were macroscopically solid and had higher post-operative morbidity than the cystic tumours in the cerebellum. The recent development of magnetic resonance imaging (MRI) provides accurate anatomical information of the lesions (especially those of the brain stem and spinal cord) even while asymptomatic. The brilliant enhancement of these tumours on MRI with Gadolinium-diethyline-triamine-pentaacetic acid (Gd-DTPA) has proved to be particularly useful.
Collapse
Affiliation(s)
- L Symon
- Gough-Cooper Department of Neurological Surgery, National Hospital for Neurology and Neurosurgery, London, U.K
| | | | | | | |
Collapse
|
249
|
Pericak-Vance MA, Nunes KJ, Whisenant E, Loeb DB, Small KW, Stajich JM, Rimmler JB, Yamaoka LH, Smith DI, Drabkin HA. Genetic mapping of dinucleotide repeat polymorphisms and von Hippel-Lindau disease on chromosome 3p25-26. J Med Genet 1993; 30:487-91. [PMID: 8100855 PMCID: PMC1016422 DOI: 10.1136/jmg.30.6.487] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
A genetic map of highly polymorphic microsatellite markers spanning the von Hippel-Lindau region (VHL) of 3p25 was constructed using the CEPH reference pedigrees. A greater than 1000:1 odds map of pter-D3S1038-RAF1-D3S651-D3S656-D3S110- D3S1255-cen was found. Genotyping of six multigenerational VHL families showed the region surrounding the D3S1038 marker to be the most likely location for the VHL gene with a peak location score of 10.04 with VHL completely linked to D3S1038. These data provide an initial high resolution genetic map of this region; D3S1038 appears to be a highly polymorphic marker that should prove useful in the future for presymptomatic diagnosis.
Collapse
Affiliation(s)
- M A Pericak-Vance
- Division of Neurology, Duke University Medical Center, Durham, North Carolina 27710
| | | | | | | | | | | | | | | | | | | |
Collapse
|
250
|
Affiliation(s)
- W C Leonhardt
- Department of Radiology, University of California, San Francisco
| | | |
Collapse
|